Company Overview - Company has submitted a listing application to the Hong Kong Stock Exchange, sponsored by Huatai International [1] - Focuses on developing potential best-in-class targeted therapies in oncology, with core technology centered around the RAS signaling pathway and synthetic lethality mechanisms [1] Product Pipeline - As of the last feasible date, the company has seven self-developed drug candidates, including four in clinical stages, one approved by the National Medical Products Administration (NMPA) and the FDA for IND, and two in preclinical stages [1] - Core product GH21 is a potential best-in-class allosteric SHP2 inhibitor currently in Phase 2 clinical trials, with IND approval for monotherapy in advanced solid tumors obtained in November 2021 [1] - GH21's combination therapies with Gossamer and Osimertinib received IND approvals in June 2024 and November 2023, respectively, and are undergoing Phase 1b/2 and Phase 2 clinical trials in China [1] Additional Drug Candidates - The RAS signaling pathway pipeline includes GH55, a potential best-in-class dual mechanism ERK1/2 inhibitor for treating MAPK pathway-activated solid tumors, currently in Phase 1 clinical trials in China [2] - The synthetic lethality pipeline includes GH56 (MTA synergistic PRMT5 inhibitor), GH2616 (KIF18A inhibitor), and GH31 (MAT2A inhibitor), all of which have received IND approvals and are in various stages of clinical trials in China [2] Market Potential - The global oncology drug market is projected to grow from $262.1 billion in 2024 to $646.1 billion by 2033, while the Chinese market is expected to increase from $37.2 billion to $123.8 billion [2] - Sub-segments such as SHP2 inhibitors and synthetic lethality drugs are anticipated to experience rapid growth in the future [2]

Company Overview - Qinhau Pharmaceutical is a biopharmaceutical company focused on developing potential best-in-class targeted therapies in oncology, with a strong pipeline of innovative candidates centered around the RAS signaling pathway and synthetic lethality mechanisms [2] - The core product GH21 is a potential best-in-class allosteric SHP2 inhibitor currently in Phase 2 clinical trials, having received IND approval for monotherapy in advanced solid tumors from the National Medical Products Administration (NMPA) in November 2021 [2][3] - The company has a pipeline of seven self-developed candidates, including four in clinical stages, one approved by both NMPA and FDA, and two in preclinical stages [3] Clinical Trials and Pipeline - GH21 is undergoing several clinical trials, including a Phase 1b/2 trial in combination with Gossamer and Osimertinib, with IND approvals obtained in June 2024 and November 2023 respectively [3] - GH55, another candidate targeting the RAS signaling pathway, is in a Phase 1 trial for MAPK pathway-activated solid tumors, having received IND approval in September and November 2022 [5] - The company is also developing five candidates leveraging synthetic lethality, including GH56 and GH2616, both in Phase 1 trials, and GH31, which has received IND approval [5][6] Market Potential - The global oncology drug market is projected to grow from $167 billion in 2020 to $262 billion by 2024, with a CAGR of 11.9%, and expected to reach $646 billion by 2033 [10] - The synthetic lethality drug market is anticipated to expand from $2.2 billion in 2020 to $4.2 billion by 2024, with a CAGR of 17.8%, and further increase to $17.6 billion by 2033 [19] - The SHP2 inhibitor market is expected to emerge in 2027, with projections of growth from approximately $329 million in 2029 to about $4.8 billion by 2033, reflecting a CAGR of 95.6% [13] Financial Performance - Qinhau Pharmaceutical reported revenues of approximately 4.69 million RMB for the fiscal year 2024, 3.73 million RMB for the nine months ending September 30, 2024, and 0.981 million RMB for the nine months ending September 30, 2025 [8][9] - The company incurred losses of approximately 1.52 billion RMB for the fiscal year 2024, 965.06 million RMB for the nine months ending September 30, 2024, and 988.87 million RMB for the nine months ending September 30, 2025 [8][9]

Group 1 - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for 10 companies, including Yingpai Pharmaceutical, which is required to clarify the pricing basis for past capital increases and share transfers, and whether there have been any instances of shareholding representation since its establishment [1] - Yingpai Pharmaceutical submitted its listing application to the Hong Kong Stock Exchange on September 26, with Goldman Sachs and CICC as joint sponsors [1] - The CSRC has requested legal opinions on the compliance of the company's past equity changes, including whether there are any unfulfilled capital contributions or irregularities in the contribution methods [1][2] Group 2 - Yingpai Pharmaceutical, established in 2009, is a biotechnology company focused on the global development of precision cancer therapies based on synthetic lethality mechanisms [2] - The company has developed a comprehensive and advanced synthetic lethality product portfolio and is one of only three companies globally with both commercial-stage PARP1/2 inhibitors and clinical-stage next-generation PARP1 selective inhibitors [2] - The core product, Senaparib, is a PARP1/2 inhibitor approved in China for first-line maintenance treatment of ovarian cancer in January 2025, showing the greatest progression-free survival benefit among approved PARP inhibitors for this indication [2]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for overseas listing applications, specifically addressing Nanjing Inpai Pharmaceutical Co., Ltd. and its compliance with various regulatory aspects [1][2]. Group 1: Regulatory Requirements - The CSRC has requested Inpai Pharmaceutical to clarify the pricing basis for its past capital increases and equity transfers, and to confirm whether there have been any violations regarding capital contributions or shareholding legality [1] - The company is also required to provide details on the compliance of its three overseas subsidiaries with foreign investment and foreign exchange registration regulations [1] - Additionally, the CSRC seeks confirmation on whether there have been any instances of shareholding representation since the company's establishment [1] Group 2: Shareholder Compliance - The company must disclose whether any shareholders holding more than 5% of shares have any domestic entities that are prohibited from holding shares under relevant laws and regulations [1] Group 3: Business Operations and Compliance - Inpai Pharmaceutical is required to explain its business scope and operations in relation to human stem cells, gene diagnosis, and treatment technologies, ensuring compliance with foreign investment policies [2] - The company must also confirm that its proposed issuance plan aligns with the regulatory guidelines for overseas listings and clarify the status of shares held by shareholders participating in the "full circulation" [2] Group 4: Company Overview - Inpai Pharmaceutical, established in 2009, is a biotechnology company focused on the global development of precision cancer therapies based on synthetic lethality mechanisms [2] - The company has developed a comprehensive and advanced portfolio of synthetic lethality products and is one of only three companies globally with both commercialized PARP1/2 inhibitors and clinical-stage next-generation PARP1 selective inhibitors [2] - Its core product, Senaparib, is a PARP1/2 inhibitor approved in January 2025 for first-line maintenance treatment of ovarian cancer in China, demonstrating the greatest progression-free survival benefit among approved PARP inhibitors for this indication [2]

Core Viewpoint - The pharmaceutical industry is experiencing a surge in IPO activities in the Hong Kong stock market, with companies like Nanjing Inpai Pharmaceutical, Guangdong Runtai Pharmaceutical, and A-share listed Borui Pharmaceutical all submitting their listing applications simultaneously, reflecting a recovery in the capital market for biopharmaceuticals and the attractiveness of Hong Kong as a financing platform [1][7]. Group 1: Company Developments - Nanjing Inpai Pharmaceutical focuses on developing precision cancer drugs based on synthetic lethality mechanisms and has a robust pipeline of DNA damage repair products [3]. - Guangdong Runtai Pharmaceutical is the fourth largest provider of marketing and supply chain solutions in China's outpatient pharmaceutical market and aims to enhance its digital marketing and supply chain through IPO funding [4][6]. - Borui Pharmaceutical is transitioning from raw material production to innovative drug development, with plans to use IPO proceeds for research and international expansion [2][8]. Group 2: Financial Highlights - Borui Pharmaceutical's revenue from raw materials reached 885 million yuan in 2023, with a 170% year-on-year increase in antiviral product sales [2]. - The company has invested 380 million yuan in its core product BGM0504, which is in the clinical trial phase for type 2 diabetes and weight loss indications, representing 60% of its total R&D investment [2]. - Runtai Pharmaceutical's business model involves purchasing products from upstream pharmaceutical companies and selling them through various e-commerce platforms, indicating a clear revenue generation strategy [6]. Group 3: Market Trends and Challenges - The current environment of improving overseas liquidity and a favorable financing climate for the biopharmaceutical sector has led to increased IPO activities [7]. - The Hong Kong market's regulatory framework allows unprofitable biotech companies to list, providing early capital access for firms like Inpai Pharmaceutical [9]. - Despite the positive trends, liquidity issues in the Hong Kong market remain a concern, with analysts noting that the enthusiasm for biopharmaceuticals in the primary market is still not sufficiently high [10][11].

Core Insights - The company, established in 2009, is a biotechnology firm focused on the global development of precision cancer therapies based on synthetic lethality mechanisms, possessing a comprehensive and advanced product portfolio [1] Product Highlights - The core product, Senaparib, is a PARP1/2 inhibitor approved for first-line maintenance treatment of ovarian cancer in China as of January 2025, demonstrating the largest progression-free survival benefit among approved PARP inhibitors for this indication [2] - Senaparib's marketing authorization application has been accepted by the European Medicines Agency, with an expected approval in the second half of 2026 [2] - The company has signed a commercial agreement with a subsidiary of Huadong Medicine for the commercialization of Senaparib in China, aiming to establish the largest gynecological oncology platform in the country [2] Pipeline Overview - The company has a diverse pipeline including several clinical-stage and preclinical assets targeting PARP and other key synthetic lethality pathways [3] - IMP1734, a next-generation selective PARP1 inhibitor, is currently in global Phase I/II trials, with plans to initiate Phase II in the second half of 2025 [3] - IMP9064, a potential first-in-class selective ATR inhibitor in China, is also in global Phase I/II trials and has received approval for combination studies with Senaparib [4] - IMP1707, a selective PARP1 inhibitor capable of penetrating the central nervous system, is undergoing Phase I clinical evaluation [5] - Other assets include preclinical candidates targeting WEE1, PKMYT1/WEE1, DHX9, ATM, USP1, and CHK1/2, as well as next-generation ADCs and protein degraders [6] Financial Performance - The company reported losses of approximately RMB 199.9 million, RMB 255.5 million, and RMB 129 million for the years ending December 31, 2023, December 31, 2024, and the six months ending June 30, 2025, respectively, primarily due to ongoing R&D investments [7] - Revenue sources include licensing income and pharmaceutical product sales, with total revenues of RMB 235.2 million for 2023 and RMB 33.5 million for the first half of 2024 [8] - The funds raised from the IPO are intended for the clinical development, regulatory approval, and commercialization of Senaparib, as well as the clinical development of key products IMP1734 and IMP9064, and other pipeline assets [8]

Core Viewpoint - Nanjing Inpai Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Goldman Sachs and CICC as joint sponsors [1] Company Overview - Established in 2009, Inpai Pharmaceutical is a biotechnology company focused on the global development of precision cancer therapies based on synthetic lethality mechanisms [4] - It is one of only three companies globally that possess both commercial-stage PARP1/2 inhibitors and clinical-stage next-generation PARP1 selective inhibitors [4] Key Product - The core product, Senaparib, is a PARP1/2 inhibitor that has been approved and commercialized in China for first-line maintenance treatment of ovarian cancer as of January 2025 [5] - Senaparib demonstrated the greatest progression-free survival benefit among approved PARP inhibitors for this indication, with good tolerability [5] - The marketing authorization application for Senaparib has been accepted by the European Medicines Agency, with approval expected in the second half of 2026 [5] - The product has been recommended for inclusion in China's National Medical Insurance Drug List, with negotiations planned for the fourth quarter of 2025 [5] - A sales service agreement has been signed with a subsidiary of Huadong Medicine to commercialize Senaparib in China, aiming to create the largest gynecological oncology platform in the country [5] - As of August 20, 2025, Senaparib has entered over 200 DTP pharmacies and covers more than 600 medical institutions [5] Product Pipeline - The company has a rich and differentiated product pipeline, including several clinical-stage and preclinical assets targeting PARP and other key synthetic lethality pathways [6] - IMP1734 is a next-generation PARP1 selective inhibitor currently in global I/II trials, with plans to initiate Phase II in the second half of 2025 [6] - IMP9064 is a potential first-in-class ATR selective inhibitor in China, also in global I/II trials, approved for combination studies with Senaparib [6] - IMP1707 is a PARP1 selective inhibitor capable of penetrating the central nervous system, currently undergoing Phase I clinical evaluation [6] - Other assets include clinical candidates targeting WEE1, PKMYT1/WEE1, DHX9, ATM, USP1, and CHK1/2, as well as next-generation ADCs and protein degraders [6] Financial Performance and Fund Utilization - The company reported losses of approximately RMB 199.9 million, RMB 255.5 million, and RMB 129 million for the years ending December 31, 2023, December 31, 2024, and the six months ending June 30, 2025, respectively, primarily due to ongoing R&D investments [7] - Revenue sources include licensing income and pharmaceutical product sales, with total revenues of RMB 235.2 million for 2023 [9] - The funds raised from the listing are planned for clinical development, regulatory approval, and commercialization of Senaparib, as well as the clinical development of key products IMP1734 and IMP9064, and other pipeline assets [9]